Hypothermic oxygenated perfusion (HOPE) safely and effectively extends acceptable donor heart preservation times: Results of the Australian and New Zealand trial.

McGiffin, DC; Kure, CE; Macdonald, PS; Jansz, PC; Emmanuel, S; Marasco, SF; Doi, A; Merry, C; Larbalestier, R; Shah, A; Geldenhuys, A; Sibal, AK; Wasywich, CA; Mathew, J; Paul, E; Cheshire, C; Leet, A; Hare, JL; Graham, S; Fraser, JF; Kaye, DM

Hypothermic oxygenated perfusion (HOPE) safely and effectively extends acceptable donor heart preservation times: Results of the Australian and New Zealand trial.

McGiffin, DC Kure, CE Macdonald, PS Jansz, PC Emmanuel, S Marasco, SF Doi, A Merry, C Larbalestier, R Shah, A Geldenhuys, A Sibal, AK Wasywich, CA Mathew, J Paul, E Cheshire, C Leet, A Hare, JL Graham, S Fraser, JF Kaye, DM

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: J Heart Lung Transplant, 2024, 43, (3), pp. 485-495
Issue Date:: 2024-03

Closed Access

	Filename	Description	Size
	1-s2.0-S1053249823021101-main.pdf	Published version	2.5 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	McGiffin, DC
dc.contributor.author	Kure, CE
dc.contributor.author	Macdonald, PS
dc.contributor.author	Jansz, PC
dc.contributor.author	Emmanuel, S
dc.contributor.author	Marasco, SF
dc.contributor.author	Doi, A
dc.contributor.author	Merry, C
dc.contributor.author	Larbalestier, R
dc.contributor.author	Shah, A
dc.contributor.author	Geldenhuys, A
dc.contributor.author	Sibal, AK
dc.contributor.author	Wasywich, CA
dc.contributor.author	Mathew, J
dc.contributor.author	Paul, E
dc.contributor.author	Cheshire, C
dc.contributor.author	Leet, A
dc.contributor.author	Hare, JL
dc.contributor.author	Graham, S
dc.contributor.author	Fraser, JF
dc.contributor.author	Kaye, DM
dc.date.accessioned	2024-12-13T04:43:17Z
dc.date.available	2023-10-25
dc.date.available	2024-12-13T04:43:17Z
dc.date.issued	2024-03
dc.identifier.citation	J Heart Lung Transplant, 2024, 43, (3), pp. 485-495
dc.identifier.issn	1053-2498
dc.identifier.issn	1557-3117
dc.identifier.uri	http://hdl.handle.net/10453/182526
dc.description.abstract	BACKGROUND: Cold static storage preservation of donor hearts for periods longer than 4 hours increases the risk of primary graft dysfunction (PGD). The aim of the study was to determine if hypothermic oxygenated perfusion (HOPE) could safely prolong the preservation time of donor hearts. METHODS: We conducted a nonrandomized, single arm, multicenter investigation of the effect of HOPE using the XVIVO Heart Preservation System on donor hearts with a projected preservation time of 6 to 8 hours on 30-day recipient survival and allograft function post-transplant. Each center completed 1 or 2 short preservation time followed by long preservation time cases. PGD was classified as occurring in the first 24 hours after transplantation or secondary graft dysfunction (SGD) occurring at any time with a clearly defined cause. Trial survival was compared with a comparator group based on data from the International Society of Heart and Lung Transplantation (ISHLT) Registry. RESULTS: We performed heart transplants using 7 short and 29 long preservation time donor hearts placed on the HOPE system. The mean preservation time for the long preservation time cases was 414 minutes, the longest being 8 hours and 47 minutes. There was 100% survival at 30 days. One long preservation time recipient developed PGD, and 1 developed SGD. One short preservation time patient developed SGD. Thirty day survival was superior to the ISHLT comparator group despite substantially longer preservation times in the trial patients. CONCLUSIONS: HOPE provides effective preservation out to preservation times of nearly 9 hours allowing retrieval from remote geographic locations.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	J Heart Lung Transplant
dc.relation.isbasedon	10.1016/j.healun.2023.10.020
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology
dc.subject.classification	Surgery
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.subject.classification	3202 Clinical sciences
dc.subject.mesh	Humans
dc.subject.mesh	Australia
dc.subject.mesh	Graft Survival
dc.subject.mesh	Heart Transplantation
dc.subject.mesh	New Zealand
dc.subject.mesh	Organ Preservation
dc.subject.mesh	Perfusion
dc.subject.mesh	Tissue Donors
dc.subject.mesh	Humans
dc.subject.mesh	Organ Preservation
dc.subject.mesh	Heart Transplantation
dc.subject.mesh	Perfusion
dc.subject.mesh	Graft Survival
dc.subject.mesh	Tissue Donors
dc.subject.mesh	Australia
dc.subject.mesh	New Zealand
dc.subject.mesh	Humans
dc.subject.mesh	Australia
dc.subject.mesh	Graft Survival
dc.subject.mesh	Heart Transplantation
dc.subject.mesh	New Zealand
dc.subject.mesh	Organ Preservation
dc.subject.mesh	Perfusion
dc.subject.mesh	Tissue Donors
dc.title	Hypothermic oxygenated perfusion (HOPE) safely and effectively extends acceptable donor heart preservation times: Results of the Australian and New Zealand trial.
dc.type	Journal Article
utslib.citation.volume	43
utslib.location.activity	United States
utslib.for	1102 Cardiorespiratory Medicine and Haematology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2024-12-13T04:43:16Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	43
utslib.citation.issue	3

Abstract:

BACKGROUND: Cold static storage preservation of donor hearts for periods longer than 4 hours increases the risk of primary graft dysfunction (PGD). The aim of the study was to determine if hypothermic oxygenated perfusion (HOPE) could safely prolong the preservation time of donor hearts. METHODS: We conducted a nonrandomized, single arm, multicenter investigation of the effect of HOPE using the XVIVO Heart Preservation System on donor hearts with a projected preservation time of 6 to 8 hours on 30-day recipient survival and allograft function post-transplant. Each center completed 1 or 2 short preservation time followed by long preservation time cases. PGD was classified as occurring in the first 24 hours after transplantation or secondary graft dysfunction (SGD) occurring at any time with a clearly defined cause. Trial survival was compared with a comparator group based on data from the International Society of Heart and Lung Transplantation (ISHLT) Registry. RESULTS: We performed heart transplants using 7 short and 29 long preservation time donor hearts placed on the HOPE system. The mean preservation time for the long preservation time cases was 414 minutes, the longest being 8 hours and 47 minutes. There was 100% survival at 30 days. One long preservation time recipient developed PGD, and 1 developed SGD. One short preservation time patient developed SGD. Thirty day survival was superior to the ISHLT comparator group despite substantially longer preservation times in the trial patients. CONCLUSIONS: HOPE provides effective preservation out to preservation times of nearly 9 hours allowing retrieval from remote geographic locations.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/182526